Variable Penetrance of a Consensus Classification Scheme for Renal Cell Carcinoma

John M. Hollingsworth, David C. Miller, Stephanie Daignault, Rajal B. Shah, Brent K. Hollenbeck

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: To evaluate the penetrance of the new pathologic standard of care, we characterized the temporal trends in histologic subtype-specific kidney cancer incidence rates. Molecular genetics have refined our understanding of kidney cancer, such that kidney cancer is now recognized as a family of tumors with distinct molecular and clinical characteristics. The histologic classification of kidney cancer has been revised to reflect this new paradigm. Methods: Using the Surveillance, Epidemiology, and End Results Program, we identified incident cases from 1983 to 2002. Tumor histologic types were assigned, using the International Classification of Disease-Oncology codes. The histologic-specific incidence rates were calculated and directly age-adjusted to the 2000 U.S. population. Results: The histologic type was available for 40,813 cases. Subsequent to the Heidelberg consensus conference, the rate of papillary histologic types rose appropriately from 0.02 in 1998 to 0.89 in 2002 per 100,000 U.S. population, and the incidence of granular cell histologic types remained relatively stable (0.22 to 0.14 cases per 100,000), despite its exclusion as a unique histologic subtype. Paradoxically, the incidence of chromophobe tumors decreased during this interval (0.03 to 0.003 cases per 100,000). Conclusions: Following the publication of the Heidelberg classification scheme, we have described the differential changes in incidence rates for newly described histologic variants. Our results suggest incomplete penetration of these guidelines. The continued reporting of granular cell histologic types is particularly noteworthy, given that it is no longer recognized as a distinct histologic subtype. Proper categorization of the histologic subtype (eg, chromophobe, papillary, clear cell) is imperative, because it may confer useful information regarding the prognosis, response to adjuvant treatment, and eligibility for clinical trials.

Original languageEnglish (US)
Pages (from-to)452-456
Number of pages5
JournalUrology
Volume69
Issue number3
DOIs
StatePublished - Mar 1 2007
Externally publishedYes

Fingerprint

Penetrance
Kidney Neoplasms
Renal Cell Carcinoma
Incidence
SEER Program
Neoplasms
International Classification of Diseases
Standard of Care
Population
Publications
Molecular Biology
Clinical Trials
Guidelines

ASJC Scopus subject areas

  • Urology

Cite this

Hollingsworth, J. M., Miller, D. C., Daignault, S., Shah, R. B., & Hollenbeck, B. K. (2007). Variable Penetrance of a Consensus Classification Scheme for Renal Cell Carcinoma. Urology, 69(3), 452-456. https://doi.org/10.1016/j.urology.2006.11.004

Variable Penetrance of a Consensus Classification Scheme for Renal Cell Carcinoma. / Hollingsworth, John M.; Miller, David C.; Daignault, Stephanie; Shah, Rajal B.; Hollenbeck, Brent K.

In: Urology, Vol. 69, No. 3, 01.03.2007, p. 452-456.

Research output: Contribution to journalArticle

Hollingsworth, JM, Miller, DC, Daignault, S, Shah, RB & Hollenbeck, BK 2007, 'Variable Penetrance of a Consensus Classification Scheme for Renal Cell Carcinoma', Urology, vol. 69, no. 3, pp. 452-456. https://doi.org/10.1016/j.urology.2006.11.004
Hollingsworth, John M. ; Miller, David C. ; Daignault, Stephanie ; Shah, Rajal B. ; Hollenbeck, Brent K. / Variable Penetrance of a Consensus Classification Scheme for Renal Cell Carcinoma. In: Urology. 2007 ; Vol. 69, No. 3. pp. 452-456.
@article{bd013c3083474e5fb5879dbba94c6592,
title = "Variable Penetrance of a Consensus Classification Scheme for Renal Cell Carcinoma",
abstract = "Objectives: To evaluate the penetrance of the new pathologic standard of care, we characterized the temporal trends in histologic subtype-specific kidney cancer incidence rates. Molecular genetics have refined our understanding of kidney cancer, such that kidney cancer is now recognized as a family of tumors with distinct molecular and clinical characteristics. The histologic classification of kidney cancer has been revised to reflect this new paradigm. Methods: Using the Surveillance, Epidemiology, and End Results Program, we identified incident cases from 1983 to 2002. Tumor histologic types were assigned, using the International Classification of Disease-Oncology codes. The histologic-specific incidence rates were calculated and directly age-adjusted to the 2000 U.S. population. Results: The histologic type was available for 40,813 cases. Subsequent to the Heidelberg consensus conference, the rate of papillary histologic types rose appropriately from 0.02 in 1998 to 0.89 in 2002 per 100,000 U.S. population, and the incidence of granular cell histologic types remained relatively stable (0.22 to 0.14 cases per 100,000), despite its exclusion as a unique histologic subtype. Paradoxically, the incidence of chromophobe tumors decreased during this interval (0.03 to 0.003 cases per 100,000). Conclusions: Following the publication of the Heidelberg classification scheme, we have described the differential changes in incidence rates for newly described histologic variants. Our results suggest incomplete penetration of these guidelines. The continued reporting of granular cell histologic types is particularly noteworthy, given that it is no longer recognized as a distinct histologic subtype. Proper categorization of the histologic subtype (eg, chromophobe, papillary, clear cell) is imperative, because it may confer useful information regarding the prognosis, response to adjuvant treatment, and eligibility for clinical trials.",
author = "Hollingsworth, {John M.} and Miller, {David C.} and Stephanie Daignault and Shah, {Rajal B.} and Hollenbeck, {Brent K.}",
year = "2007",
month = "3",
day = "1",
doi = "10.1016/j.urology.2006.11.004",
language = "English (US)",
volume = "69",
pages = "452--456",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Variable Penetrance of a Consensus Classification Scheme for Renal Cell Carcinoma

AU - Hollingsworth, John M.

AU - Miller, David C.

AU - Daignault, Stephanie

AU - Shah, Rajal B.

AU - Hollenbeck, Brent K.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Objectives: To evaluate the penetrance of the new pathologic standard of care, we characterized the temporal trends in histologic subtype-specific kidney cancer incidence rates. Molecular genetics have refined our understanding of kidney cancer, such that kidney cancer is now recognized as a family of tumors with distinct molecular and clinical characteristics. The histologic classification of kidney cancer has been revised to reflect this new paradigm. Methods: Using the Surveillance, Epidemiology, and End Results Program, we identified incident cases from 1983 to 2002. Tumor histologic types were assigned, using the International Classification of Disease-Oncology codes. The histologic-specific incidence rates were calculated and directly age-adjusted to the 2000 U.S. population. Results: The histologic type was available for 40,813 cases. Subsequent to the Heidelberg consensus conference, the rate of papillary histologic types rose appropriately from 0.02 in 1998 to 0.89 in 2002 per 100,000 U.S. population, and the incidence of granular cell histologic types remained relatively stable (0.22 to 0.14 cases per 100,000), despite its exclusion as a unique histologic subtype. Paradoxically, the incidence of chromophobe tumors decreased during this interval (0.03 to 0.003 cases per 100,000). Conclusions: Following the publication of the Heidelberg classification scheme, we have described the differential changes in incidence rates for newly described histologic variants. Our results suggest incomplete penetration of these guidelines. The continued reporting of granular cell histologic types is particularly noteworthy, given that it is no longer recognized as a distinct histologic subtype. Proper categorization of the histologic subtype (eg, chromophobe, papillary, clear cell) is imperative, because it may confer useful information regarding the prognosis, response to adjuvant treatment, and eligibility for clinical trials.

AB - Objectives: To evaluate the penetrance of the new pathologic standard of care, we characterized the temporal trends in histologic subtype-specific kidney cancer incidence rates. Molecular genetics have refined our understanding of kidney cancer, such that kidney cancer is now recognized as a family of tumors with distinct molecular and clinical characteristics. The histologic classification of kidney cancer has been revised to reflect this new paradigm. Methods: Using the Surveillance, Epidemiology, and End Results Program, we identified incident cases from 1983 to 2002. Tumor histologic types were assigned, using the International Classification of Disease-Oncology codes. The histologic-specific incidence rates were calculated and directly age-adjusted to the 2000 U.S. population. Results: The histologic type was available for 40,813 cases. Subsequent to the Heidelberg consensus conference, the rate of papillary histologic types rose appropriately from 0.02 in 1998 to 0.89 in 2002 per 100,000 U.S. population, and the incidence of granular cell histologic types remained relatively stable (0.22 to 0.14 cases per 100,000), despite its exclusion as a unique histologic subtype. Paradoxically, the incidence of chromophobe tumors decreased during this interval (0.03 to 0.003 cases per 100,000). Conclusions: Following the publication of the Heidelberg classification scheme, we have described the differential changes in incidence rates for newly described histologic variants. Our results suggest incomplete penetration of these guidelines. The continued reporting of granular cell histologic types is particularly noteworthy, given that it is no longer recognized as a distinct histologic subtype. Proper categorization of the histologic subtype (eg, chromophobe, papillary, clear cell) is imperative, because it may confer useful information regarding the prognosis, response to adjuvant treatment, and eligibility for clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=33947280961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947280961&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2006.11.004

DO - 10.1016/j.urology.2006.11.004

M3 - Article

C2 - 17382143

AN - SCOPUS:33947280961

VL - 69

SP - 452

EP - 456

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -